Diakonos Oncology Corp.

About Diakonos Oncology Corp.

Diakonos Oncology is a clinical-stage biotechnology company focused on developing innovative immunotherapy solutions, specifically Dendritic Cell Vaccines (DCV), for difficult-to-treat cancers. Their mission is to redefine the potential of immunotherapy by harnessing the body's natural anti-viral immune response, with their lead product DOC1021 receiving FDA's Fast Track designation.

Products & Services

DOC1021 Dendritic Cell Vaccine:A novel immunotherapy for cancer that uses a proprietary 'double-loading' technique to trick the body into perceiving cancer cells as virally infected, mobilizing the immune system to destroy them. Currently in clinical trials for Glioblastoma (Phase 2) and Pancreatic Adenocarcinoma (Phase 1).

Specialties

Immunotherapy Dendritic Cell Vaccines Cancer Treatment Clinical Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 7000000 MR: - FA: $7 million FAN: 7000000	D: 2025-12-10 FD: 2025-12-10	1 investors
2	RT: SAFE Private Placement T: - FT: SAFE Private Placement	A: 20000000 MR: - FA: $20 million FAN: 20000000	D: 2025-05-30 FD: 2025-05-30	4 investors
3	RT: Seed T: - FT: Seed	A: 11400000 MR: - FA: 11.4 million FAN: 11400000	D: 2024-08-26 FD: 2024-08-26	1 investors

Grant Latest

2025-12-10

$7.0M

1 investor (Pro only)

SAFE Private Placement 2025-05-30

$20.0M

Seed 2024-08-26

$11.4M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mike Wicks

CEO and Board Member

D

Dan Faust

Chairman

P

Paul Lammers

Board Member

J

Jay Hartenbach

President, COO

L

Laura Aguilar

CMO

S

Sonja Nelson

CFO

View 11 more team members with Pro

Unlock Full Team Directory

Recent News